- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04723875
Postoperative Adjuvant Chemotherapy in Early-stage Cervical Cancer That Not Meet Criteria of Adjuvant Therapeutic According to NCCN Guideline
January 21, 2021 updated by: Ding Ma, Huazhong University of Science and Technology
Postoperative Adjuvant Chemotherapy in Early-stage Cervical Cancer That Not Meet Criteria of Adjuvant Therapeutic According to NCCN Guideline:A Prospective Multicenter Randomized Controlled Clinical Trial
This is a prospective, phase 3 randomized controlled clinical trial.
Cervical cancer patients who undergo radical surgery but do not meet criteria of adjuvant therapy according to NCCN guideline are enrolled to receive adjuvant chemotherapy.
The primary endpoint was disease-free survival (DFS) rate at 3 year.
The secondary endpoints were 5-year DFS, overall survival (OS) and safety.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
306
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Hubei
-
Wuhan, Hubei, China, 430000
- Recruiting
- Tongji Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 70 years (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Female
Description
Inclusion Criteria:
- Patients with 2018 FIGO staged IB1,IB2, IIA1 cervical cancer.
- The initial treatment was radical hysterectomy + pelvic lymphadenectomy by laparotomy or laparoscopy with cervical cancer foci sealed before dissection of the vagina and without uterine manipulator.
- Postoperative pathological diagnosis was cervical squamous cell carcinoma, cervical adenosquamous cell carcinoma or cervical adenocarcinoma.
- Assessment of risk factors not meeting Sedlis criteria (NCCN guideline),but having one of following factors :(1)Deep stromal infiltration(≥2/3 layer);(2)histopathological differentiation grade G2 ~ G3;(3)Lymph-vascular space invasion ;(4)Adenocarcinoma or adenosquamous cell carcinoma;(5)Tumor size ≥2cm.
- Age:18-70 years old.
- WBC≥3.5*10^9/L, NEU≥1.5*10^9/L, Platelet≥80×10^9 /L; AST and ALT ≤1.5 times normal upper limit; Total bilirubin ≤1.5 times the upper limit of normal value; serum creatinine and blood urea nitrogen ≤the upper limit of normal value.
- Eastern Cooperative Oncology Group score 0-1.
- Well-compliance and willing to keep in touch.
- Willing to participate in this study, and sign the informed consent.
Exclusion Criteria:
- Postoperative pathology has high-risk factors(lymph node metastasis, parametrial infiltration or positive surgical margin)or meets Sedlis criteria.
- Participate in other clinical trials at the same time.
- Comorbidity including but not limited to: heart diseases (grade III-IV cardiac insufficiency (NYHA standard); central nervous system diseases or nonfunctional behavior; hematological system diseases; liver or kidney malformation or history of surgery.
- Persons without disposing capacity.
- Drug and/or alcohol abuse.
- Unable or unwilling to sign informed consents.
- Not eligible for the study judged by researchers.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Adjuvant chemotherapy group
Participant will receive 3 cycles of adjuvant chemotherapy if having any of the following factors;participant will receive 6 cycles of adjuvant chemotherapy if having ≥2 of the following factors. Risk factors: (1) Deep cervical invasion(≥ 2/3);(2)Differentiation grade 2-3;(3)Lymphatic vascular space infiltration;(4)Adenocarcinoma or adenosquamous carcinoma;(5)Tumor size ≥ 2cm |
Paclitaxel 135-175mg/m2 over 3 hours or docetaxel 70-75 mg/m2, 30min + Cisplatin 75-80mg/m2 or carboplatin AUC = 5, repeat per 21 days.
|
NO_INTERVENTION: Control group
The participants receive no intervention.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Disease-free survival (DFS)
Time Frame: 3 year
|
DFS is defined as the time interval between the date of random assignment and the date of the first documented evidence of relapse at any site or death related to cancer (including toxicity), whichever occurred first.
|
3 year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall survival (OS)
Time Frame: 3 year
|
OS is defined as the time from the date of randomization until death of any cause.
|
3 year
|
5-year DFS/OS
Time Frame: 5 years
|
DFS is defined as the time interval between the date of random assignment and the date of the first documented evidence of relapse at any site or death related to cancer (including toxicity), whichever occurred first.
OS is defined as the time from the date of randomization until death of any cause.
|
5 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ANTICIPATED)
February 1, 2021
Primary Completion (ANTICIPATED)
January 31, 2026
Study Completion (ANTICIPATED)
January 31, 2026
Study Registration Dates
First Submitted
January 21, 2021
First Submitted That Met QC Criteria
January 21, 2021
First Posted (ACTUAL)
January 26, 2021
Study Record Updates
Last Update Posted (ACTUAL)
January 26, 2021
Last Update Submitted That Met QC Criteria
January 21, 2021
Last Verified
January 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms
- Urogenital Neoplasms
- Neoplasms by Site
- Uterine Neoplasms
- Genital Neoplasms, Female
- Uterine Cervical Diseases
- Uterine Diseases
- Uterine Cervical Neoplasms
- Molecular Mechanisms of Pharmacological Action
- Antineoplastic Agents
- Tubulin Modulators
- Antimitotic Agents
- Mitosis Modulators
- Antineoplastic Agents, Phytogenic
- Docetaxel
- Carboplatin
- Paclitaxel
- Cisplatin
Other Study ID Numbers
- 2020-S113
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cervical Cancer
-
University of California, San DiegoWithdrawnCervical Cancer | Cervical Cancer Stage | Cervical Cancer Stage IB2 | Cervical Cancer Stage IB1 | Cervical Cancer Stage I | Cervical Cancer Stage IB | Cervical Cancer Stage II | Cervical Cancer Stage IIa | Cervical Cancer, Stage IIB | Cervical Cancer, Stage III | Cervical Cancer Stage IIIB | Cervical Cancer... and other conditionsUnited States
-
M.D. Anderson Cancer CenterWithdrawnStage IB3 Cervical Cancer FIGO 2018 | Stage II Cervical Cancer FIGO 2018 | Stage IIA Cervical Cancer FIGO 2018 | Stage IIA1 Cervical Cancer FIGO 2018 | Stage IIA2 Cervical Cancer FIGO 2018 | Stage IIB Cervical Cancer FIGO 2018 | Stage III Cervical Cancer FIGO 2018 | Stage IIIA Cervical Cancer FIGO... and other conditions
-
Abramson Cancer Center of the University of PennsylvaniaWithdrawnCervical Cancer | Stage IB Cervical Cancer | Stage IIA Cervical Cancer | Stage IIB Cervical Cancer | Stage III Cervical Cancer | Stage IVA Cervical Cancer
-
National Cancer Institute (NCI)CompletedCervical Adenocarcinoma | Cervical Squamous Cell Carcinoma | Stage IB Cervical Cancer | Stage IIA Cervical Cancer | Stage IIB Cervical Cancer | Stage III Cervical Cancer | Stage IVA Cervical Cancer | Stage IVB Cervical CancerUnited States
-
Mayo ClinicNational Cancer Institute (NCI)RecruitingCervical Adenosquamous Carcinoma | Cervical Squamous Cell Carcinoma, Not Otherwise Specified | Recurrent Cervical Carcinoma | Stage IB3 Cervical Cancer FIGO 2018 | Stage II Cervical Cancer FIGO 2018 | Stage IIA Cervical Cancer FIGO 2018 | Stage IIA1 Cervical Cancer FIGO 2018 | Stage IIA2 Cervical... and other conditionsUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingStage IA Cervical Cancer | Stage IB Cervical Cancer | Stage IA1 Cervical Cancer | Stage IA2 Cervical Cancer | Stage IB1 Cervical Cancer | Stage IB2 Cervical Cancer | Stage IB3 Cervical CancerUnited States
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)CompletedCervical Adenocarcinoma | Cervical Squamous Cell Carcinoma | Stage IB Cervical Cancer | Stage IIA Cervical Cancer | Stage IIB Cervical Cancer | Stage III Cervical Cancer | Stage IVA Cervical CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)CompletedRecurrent Cervical Cancer | Stage IVA Cervical Cancer | Stage IVB Cervical Cancer | Stage IIIA Cervical Cancer | Stage IIIB Cervical CancerUnited States
-
Shanghai First Maternity and Infant HospitalNot yet recruitingCervical Cancer, Stage IIB | Cervical Cancer Stage IIIB | Cervical Cancer Stage IIIA | Cervical Cancer, Stage IVA
-
Institut de Cancérologie de LorraineCompletedCervical Adenocarcinoma | Stage IB Cervical Cancer | Stage III Cervical Cancer | Stage II Cervical CancerFrance
Clinical Trials on Paclitaxel or docetaxel + Cisplatin or carboplatin
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.RecruitingRecurrent Squamous Cell Carcinoma of the Head and Neck | Metastatic Squamous Cell CarcinomaChina
-
Shanghai Kechow Pharma, Inc.Not yet recruiting
-
BioNumerik Pharmaceuticals, Inc.Lantern Pharma Inc. became Sponsor of Tavocept (BNP7787) IND 051014 as of...CompletedNon-small Cell Lung CancerPoland, Russian Federation, Bulgaria, United States, Romania, Ukraine
-
ImmunityBio, Inc.Active, not recruitingNon Small Cell Lung CancerUnited States
-
Optimal Health ResearchCompletedBreast Cancer | Lung Cancer | Prostate CancerUnited States
-
Seoul National University HospitalNot yet recruiting
-
Hunan Cancer HospitalJiangsu HengRui Medicine Co., Ltd.Not yet recruiting
-
Cancer Institute and Hospital, Chinese Academy...Peking University Cancer Hospital & InstituteRecruitingEsophageal Neoplasm Metastatic | Esophageal Cancer Stage IVbChina
-
Hunan Cancer HospitalJiangsu HengRui Medicine Co., Ltd.Recruiting
-
Ruijin HospitalNot yet recruitingCervical Squamous Cell CarcinomaChina